Mirum Pharmaceuticals, Inc. Income Taxes Paid
Mirum Pharmaceuticals, Inc. (MIRM) reported Income Taxes Paid of $1.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. income taxes paid, net for the quarter ending 2026-06-30 was $907.00K, a 38.92% decline year-over-year.
- Mirum Pharmaceuticals, Inc. income taxes paid, net for the quarter ending 2026-03-31 was $220.00K, a 35.80% increase year-over-year.
- Mirum Pharmaceuticals, Inc. income taxes paid, net for the quarter ending 2025-12-31 was $6.00K, a 97.42% decline year-over-year.
- Mirum Pharmaceuticals, Inc. income taxes paid, net for the quarter ending 2025-09-30 was $504.00K, a 16.67% increase year-over-year.
- Mirum Pharmaceuticals, Inc. income taxes paid, net for fiscal 2025 was $2.16M, a 114.84% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. income taxes paid, net for fiscal 2024 was $1.00M, a 703.20% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. income taxes paid, net for fiscal 2023 was $125.00K.
- Mirum Pharmaceuticals, Inc. income taxes paid, net for fiscal 2022 was $0.00.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $907.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.13M 10-Q · filed 2026-08-05 | $1.13M derived: sum of 3 quarters · filed 2026-08-05 | $1.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $220.00K 10-Q · filed 2026-05-06 | $226.00K derived: sum of 2 quarters · filed 2026-05-06 | $730.00K derived: sum of 3 quarters · filed 2026-05-06 | $2.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $510.00K derived: sum of 2 quarters · filed 2026-02-25 | $2.00M derived: sum of 3 quarters · filed 2026-08-05 | $2.16M 10-K · filed 2026-02-25 |
| 2025-09-30 | $504.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.99M derived: sum of 2 quarters · filed 2026-08-05 | $2.15M 10-Q · filed 2025-11-04 | $2.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.65M 10-Q · filed 2026-08-05 | $1.88M derived: sum of 3 quarters · filed 2026-08-05 | $2.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $162.00K 10-Q · filed 2026-05-06 | $395.00K derived: sum of 2 quarters · filed 2026-05-06 | $827.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.03M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $665.00K derived: sum of 2 quarters · filed 2026-02-25 | $865.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.00M 10-K · filed 2026-02-25 |
| 2024-09-30 | $432.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $632.00K derived: sum of 2 quarters · filed 2025-11-04 | $771.00K 10-Q · filed 2025-11-04 | $896.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $339.00K 10-Q · filed 2025-08-06 | $464.00K derived: sum of 3 quarters · filed 2026-02-25 | $464.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $139.00K 10-Q · filed 2025-05-07 | $264.00K derived: sum of 2 quarters · filed 2026-02-25 | $264.00K derived: sum of 3 quarters · filed 2026-02-25 | $264.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $125.00K derived: sum of 2 quarters · filed 2026-02-25 | $125.00K derived: sum of 3 quarters · filed 2026-02-25 | $125.00K 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |